Infinity Bio Hosts Community Event for Baltimore’s Brightest Students

Future scientists hail from Baltimore City’s Coppin Academy High School

BALTIMORE--(BUSINESS WIRE)--Infinity Bio, Inc., a biotechnology company specializing in antibody reactome profiling, hosted a special community event aimed at engaging and inspiring Baltimore children with an interest in STEM. The event took place on July 22, 2024, at Infinity Bio’s office and laboratory at 6200 Seaforth Street, Baltimore, MD, and featured various activities designed to spark interest in science and technology.

Infinity Bio, founded in 2023, focuses on leveraging its proprietary MIPSA technology to advance antibody reactome profiling, providing crucial insights into disease mechanisms while advancing the development of therapeutics and diagnostics. The company’s core technology was developed at Johns Hopkins University in Dr. H. Benjamin Larman's Laboratory of Precision Immunology. Students from Coppin Academy High School, operated by Coppin State University, had the opportunity to participate in hands-on training, meet scientists, and discover the fascinating field of immunology. The annual event is part of Infinity Bio's ongoing commitment to giving back to the community and supporting educational initiatives.

Dr. Quinhon Scott, Charter School Program Manager of Coppin State University, expressed her gratitude, stating, “We are incredibly thankful to Infinity Bio for providing our students with this invaluable opportunity. Events like these play a crucial role in nurturing our students' interest in STEM and broadening their horizons. It’s inspiring to see our students engage with cutting-edge science and envision their futures in such a dynamic field.”

“Empowering the next generation of scientists starts with providing them access to resources and opportunities,” said Joy M. Nassif, CEO of Infinity Bio. “We are thrilled to host this event in Baltimore and to contribute to the community in a meaningful way. Our goal is to inspire curiosity and a love for science among these young minds.”

Larman added: “There is nothing more rewarding than passing along my love of immunology to the next generation of biomedical researchers. The future of human health is their hands, and so much of human health is impacted by the immune system.”

For more information on Infinity Bio, please visit www.infinitybio.com. To schedule interviews or to access photos/footage from the event, contact [e-mail].

ABOUT INFINITY BIO
Infinity Bio, Inc. is a biotechnology company that provides detailed insights into the immune system using its proprietary antibody reactome profiling platform. The company’s core technology comprehensively measures antibody reactivities against all known human viruses, human proteins (autoimmunity), and allergen proteins. Infinity Bio's MIPSA technology was developed at Johns Hopkins University in Dr. H. Benjamin Larman's Laboratory of Precision Immunology. It builds off of decades of work in the fields of genomics, proteomics, immunology, and bioinformatics to enable best-in-class data quality and cost efficiency.